Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ALKS | Alkermes plc

Healthcare | Drug Manufacturers - Specialty & Generic | Ireland | NASD

Index	RUT	P/E	51.31	EPS (ttm)	0.57	Insider Own	1.43%	Shs Outstand	164.38M	Perf Week	-2.77%
Market Cap	4.85B	Forward P/E	13.69	EPS next Y	2.13	Insider Trans	-3.01%	Shs Float	164.18M	Perf Month	5.59%
Income	102.99M	PEG	2.12	EPS next Q	0.44	Inst Own	93.66%	Short Float / Ratio	5.78% / 5.41	Perf Quarter	-10.90%
Sales	1.46B	P/S	3.32	EPS this Y	375.00%	Inst Trans	-1.25%	Short Interest	9.48M	Perf Half Y	9.85%
Book/sh	7.69	P/B	3.78	EPS next Y	31.66%	ROA	4.97%	Target Price	36.67	Perf Year	29.51%
Cash/sh	4.98	P/C	5.85	EPS next 5Y	24.26%	ROE	8.72%	52W Range	21.75 - 33.71	Perf YTD	11.37%
Dividend	-	P/FCF	25.27	EPS past 5Y	1.24%	ROI	6.24%	52W High	-13.68%	Beta	0.59
Dividend %	-	Quick Ratio	2.48	Sales past 5Y	4.91%	Gross Margin	81.28%	52W Low	33.79%	ATR	0.79
Employees	2280	Current Ratio	2.87	Sales Q/Q	123.52%	Oper. Margin	7.56%	RSI (14)	47.73	Volatility	2.23% 2.91%
Optionable	Yes	Debt/Eq	0.30	EPS Q/Q	-	Profit Margin	7.04%	Rel Volume	0.48	Prev Close	29.02
Shortable	Yes	LT Debt/Eq	0.29	Earnings	Jul 26 BMO	Payout	-	Avg Volume	1.75M	Price	29.10
Recom	2.00	SMA20	-0.35%	SMA50	-0.60%	SMA200	1.59%	Volume	843,736	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24
Jul-30-20	Downgrade	Goldman	Neutral → Sell	$19 → $15
Feb-14-20	Reiterated	H.C. Wainwright	Neutral	$26 → $25
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral	$21
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral	$31 → $20
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$30 → $20
Jul-15-19	Upgrade	Goldman	Sell → Neutral
May-31-19	Initiated	H.C. Wainwright	Neutral
May-01-19	Downgrade	Citigroup	Buy → Neutral

Show Previous Ratings

Sep-22-23 12:49PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
Sep-21-23 01:00PM	Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month (ACCESSWIRE)
Sep-19-23 11:05AM	Alkermes Pathways Research Awards Is Now Accepting Applications! (ACCESSWIRE)
Sep-18-23 01:15PM	Alkermes Commemorates World Suicide Prevention Day (ACCESSWIRE)
Sep-15-23 06:15PM	Alkermes (ALKS) Stock Moves -0.84%: What You Should Know (Zacks)
10:50AM	Loading…
Sep-13-23 10:50AM	For Potential Alkermes Buyers, There's a Key Price Level to Watch (TheStreet.com)
Sep-11-23 07:00AM	Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress (PR Newswire)
Sep-08-23 06:15PM	Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Sep-07-23 03:15PM	Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program (ACCESSWIRE)
11:31AM	Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue? (Zacks)
09:30AM	Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:00AM	Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program (PR Newswire)
Sep-06-23 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Sep-05-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
Sep-01-23 06:30PM	Sleep Number, Newell Brands, and More Stocks See Action From Activist Investors (Barrons.com)
11:31AM	Loading…
11:31AM	Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-31-23 02:45PM	Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants(R) Program (ACCESSWIRE)
11:02AM	Alkermes (ALKS) Grants Teva License to Market Generic Drug (Zacks)
07:00AM	Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program (PR Newswire)
Aug-30-23 07:00AM	Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation (PR Newswire) +7.10%
Aug-28-23 10:35AM	Alkermes Honors Women's Equality Day (ACCESSWIRE)
Aug-25-23 11:31AM	Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report? (Zacks)
Aug-21-23 10:45AM	Back to College? Talk to Your Student About Alcohol (ACCESSWIRE)
Aug-10-23 05:21AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Aug-09-23 08:32AM	Should Weakness in Alkermes plc's (NASDAQ:ALKS) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? (Simply Wall St.)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Jul-27-23 10:24AM	Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates (Zacks)
Jul-26-23 11:05AM	GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance (Zacks)
09:30AM	Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:11AM	Loading…
07:11AM	Alkermes: Q2 Earnings Snapshot (AP Finance)
07:00AM	Alkermes plc Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-25-23 11:21AM	Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts (Zacks)
Jul-24-23 01:45PM	Alkermes Awarded 2023 Platinum Bell Seal for Workplace Mental Health (ACCESSWIRE)
10:44AM	Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab (Zacks)
Jul-21-23 12:05PM	Vir Biotechnology (VIR) Down on Influenza Study Failure (Zacks)
09:30AM	Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 10:02AM	Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-19-23 04:00PM	Alkermes to Report Second Quarter Financial Results on July 26, 2023 (PR Newswire)
11:30AM	Alkermes Celebrates Pride Month (ACCESSWIRE)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-17-23 11:40AM	Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion (Zacks)
11:15AM	Celebrating 15 Years of Alkermes in Action (ACCESSWIRE)
Jul-13-23 09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
07:56AM	Alkermes plc (NASDAQ:ALKS) Shares Could Be 45% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-11-23 08:44AM	Implied Volatility Surging for Alkermes (ALKS) Stock Options (Zacks)
Jul-10-23 09:55AM	Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jul-06-23 08:00AM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? (Investor's Business Daily)
Jul-04-23 07:56AM	Here's Why You Should Add Alkermes (ALKS) to Your Portfolio (Zacks)
Jun-29-23 10:50AM	Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders (PR Newswire)
10:09AM	Alkermes wins battle against Sarissa in closely watched boardroom fight (Reuters)
09:57AM	UPDATE 3-Alkermes wins battle against Sarissa in closely watched boardroom fight (Reuters)
09:20AM	Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - source (Reuters)
Jun-28-23 07:30AM	Sarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard Gaynor (Business Wire)
Jun-27-23 01:45PM	Tips for Finding LGBTQ+ Competent Mental Health Care (ACCESSWIRE)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-26-23 07:37AM	Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders (Business Wire)
07:00AM	Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders (PR Newswire)
Jun-22-23 06:25AM	Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board (Business Wire)
Jun-21-23 02:15PM	DYK: The LGBTQ+ Community Is at Greater Risk for Substance Abuse (ACCESSWIRE)
08:00AM	Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees (PR Newswire)
Jun-20-23 11:17AM	Shares of Alkermes Look Ready to Breakout (TheStreet.com)
09:33AM	Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board (Business Wire)
09:24AM	ISS recommends one of Sarissa's three nominees for Alkermes board (Reuters)
07:00AM	Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board (PR Newswire)
Jun-16-23 06:40PM	Alkermes and Cogent Biosciences Stock See Action From Activist Investors (Barrons.com)
01:50PM	Juneteenth Reflections From Alkermes' Harold Weekes, Sr. Director, Human Resources (ACCESSWIRE)
Jun-15-23 12:15PM	Reflecting on Stigmas Surrounding Mens Health During Mens Health Week 2023 (ACCESSWIRE)
07:58AM	Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board (Business Wire)
Jun-14-23 02:30PM	Alkermes Participates in ALPFAs Latina Summit (ACCESSWIRE)
Jun-13-23 07:14PM	UPDATE 2-Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes (Reuters)
01:52PM	Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes (Reuters)
01:43PM	Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes (Reuters)
07:20AM	Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes (Business Wire)
07:00AM	Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors (PR Newswire)
Jun-09-23 07:00AM	Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board (Business Wire)
Jun-08-23 07:00AM	Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation (PR Newswire)
Jun-07-23 01:15PM	The Impact of Alkermes Inspiration Grants (ACCESSWIRE)
12:31PM	Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View (Zacks)
Jun-06-23 03:50PM	Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements (Benzinga)
06:00AM	Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations (PR Newswire)
Jun-05-23 07:00AM	Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders (Business Wire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 04:01PM	Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc (PR Newswire)
11:31AM	Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report? (Zacks)
May-31-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
11:30AM	Why Is Vertex (VRTX) Down 6% Since Last Earnings Report? (Zacks)
May-26-23 11:31AM	Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue? (Zacks)
May-25-23 04:15PM	Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value (PR Newswire)
May-16-23 07:00AM	Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences (PR Newswire)
May-09-23 07:00AM	Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
May-08-23 04:41PM	Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process (PR Newswire)
12:35PM	Alkermes Named Among Top 100 Companies Leading in Wellbeing by Ibec (ACCESSWIRE)
May-06-23 08:17AM	Insufficient Growth At Alkermes plc (NASDAQ:ALKS) Hampers Share Price (Simply Wall St.)
May-04-23 10:30AM	Alkermes Athlone Shortlisted for Gradirleands 17th Annual Graduate Recruitment Awards (ACCESSWIRE)
May-02-23 01:30PM	Alkermes Athlone Receives Award at Irelands 2023 Health & Safety Excellence Awards (ACCESSWIRE)
May-01-23 01:30PM	Alkermes Inspiration Grants Now Open for Applications (ACCESSWIRE)
Apr-27-23 09:04AM	Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates (Zacks)
Apr-26-23 01:15PM	Clinical Trials Integral to Providing More Treatment Options for Platinum-Resistant Ovarian Cancer (PROC) (ACCESSWIRE) -6.98%
09:30AM	Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAURENCIN CATO T	Director	Jun 08	Option Exercise	22.97	2,638	60,595	10,117	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 08	Sale	31.85	2,638	84,020	7,479	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 07	Option Exercise	22.97	2,800	64,316	10,279	Jun 07 05:12 PM
LAURENCIN CATO T	Director	Jun 07	Sale	31.50	2,800	88,200	7,479	Jun 07 05:12 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30	Option Exercise	20.43	19,634	401,123	68,118	May 30 08:16 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30	Sale	28.93	27,134	784,862	40,984	May 30 08:16 PM
Wysenski Nancy	Director	May 09	Option Exercise	31.13	41,250	1,284,112	57,079	May 10 04:34 PM
Wysenski Nancy	Director	May 09	Sale	31.24	41,250	1,288,786	15,829	May 10 04:34 PM
Daglio David Angelo Jr.	Director	Nov 14	Buy	23.31	35,000	815,734	80,000	Nov 16 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS | Alkermes plc

Upgrade your FINVIZ experience